-
Posted by
Two Blokes Mon at 12:00 PM -
Filed in
Stock
-
2 views
Shares in Arecor Therapeutics PLC (AIM:AREC) rose 10% in morning trading after the company announced a new development deal with US biotech group Skye Bioscience to improve the formulation of a mid-stage obesity drug. The Cambridge-based firm will apply its proprietary Arestat technology to create a more concentrated version of nimacimab, a monoclonal antibody that targets the CB1 receptor, which plays a role in appetite and metabolism.
